CA3158321A1 - Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies - Google Patents

Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies

Info

Publication number
CA3158321A1
CA3158321A1 CA3158321A CA3158321A CA3158321A1 CA 3158321 A1 CA3158321 A1 CA 3158321A1 CA 3158321 A CA3158321 A CA 3158321A CA 3158321 A CA3158321 A CA 3158321A CA 3158321 A1 CA3158321 A1 CA 3158321A1
Authority
CA
Canada
Prior art keywords
capivasertib
acalabrutinib
administered
pharmaceutically acceptable
cell lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3158321A
Other languages
English (en)
French (fr)
Inventor
Hannah DRY
Brandon Willis
Andrew Bloecher
Jerome METTETAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CA3158321A1 publication Critical patent/CA3158321A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3158321A 2019-11-04 2020-10-30 Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies Pending CA3158321A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930208P 2019-11-04 2019-11-04
US62/930,208 2019-11-04
PCT/EP2020/080493 WO2021089419A1 (en) 2019-11-04 2020-10-30 Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies

Publications (1)

Publication Number Publication Date
CA3158321A1 true CA3158321A1 (en) 2021-05-14

Family

ID=73043259

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3158321A Pending CA3158321A1 (en) 2019-11-04 2020-10-30 Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies

Country Status (14)

Country Link
US (1) US12691113B2 (cg-RX-API-DMAC7.html)
EP (1) EP4054582B1 (cg-RX-API-DMAC7.html)
JP (1) JP7575454B2 (cg-RX-API-DMAC7.html)
KR (1) KR102984130B1 (cg-RX-API-DMAC7.html)
CN (1) CN114728003B (cg-RX-API-DMAC7.html)
AU (1) AU2020381240C1 (cg-RX-API-DMAC7.html)
CA (1) CA3158321A1 (cg-RX-API-DMAC7.html)
DK (1) DK4054582T3 (cg-RX-API-DMAC7.html)
ES (1) ES3055126T3 (cg-RX-API-DMAC7.html)
FI (1) FI4054582T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022005250A (cg-RX-API-DMAC7.html)
PL (1) PL4054582T3 (cg-RX-API-DMAC7.html)
PT (1) PT4054582T (cg-RX-API-DMAC7.html)
WO (1) WO2021089419A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230286A2 (en) * 2022-05-25 2023-11-30 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
WO2024104561A1 (en) * 2022-11-15 2024-05-23 Astrazeneca Ab Therapeutic combinations of capivasertib and venetoclax

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0818533B8 (pt) 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
CN103889987B (zh) 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
AU2014360537B2 (en) * 2013-12-04 2017-09-07 Gilead Sciences, Inc. Methods for treating cancers
EP3076974A1 (en) * 2013-12-05 2016-10-12 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
JP6785804B2 (ja) * 2015-06-23 2020-11-18 ギリアド サイエンシズ, インコーポレイテッド B細胞悪性腫瘍を治療するための組合せ療法
US20170071962A1 (en) 2015-09-11 2017-03-16 Acerta Pharma B.V. Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
BR112017002594A2 (pt) * 2015-12-17 2017-12-19 Gilead Sciences Inc compostos inibidores de cinase de ligação de tank
CN107344940B (zh) * 2016-05-06 2020-04-21 广东东阳光药业有限公司 Btk抑制剂及其用途
WO2018097977A1 (en) * 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
AU2018335617B2 (en) * 2017-09-25 2021-12-09 Astrazeneca Ab Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer
TW202014184A (zh) * 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合
KR20250119664A (ko) 2018-08-29 2025-08-07 아세르타 파마. 비.브이. 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정

Also Published As

Publication number Publication date
JP7575454B2 (ja) 2024-10-29
JP2023501317A (ja) 2023-01-18
PL4054582T3 (pl) 2026-02-16
EP4054582B1 (en) 2025-09-03
FI4054582T3 (fi) 2025-12-04
KR20220098175A (ko) 2022-07-11
EP4054582A1 (en) 2022-09-14
DK4054582T3 (da) 2025-12-01
PT4054582T (pt) 2025-12-10
AU2020381240C1 (en) 2024-02-15
WO2021089419A1 (en) 2021-05-14
AU2020381240A1 (en) 2022-06-23
US20220401442A1 (en) 2022-12-22
KR102984130B1 (ko) 2026-07-01
CN114728003A (zh) 2022-07-08
US12691113B2 (en) 2026-07-28
AU2020381240B2 (en) 2023-09-07
MX2022005250A (es) 2022-06-08
ES3055126T3 (en) 2026-02-10
CN114728003B (zh) 2025-01-28

Similar Documents

Publication Publication Date Title
JP6742391B2 (ja) 併用療法
TWI607754B (zh) 醫藥組合
JP6911047B2 (ja) がんの処置のための、Notch阻害剤およびCDK4/6阻害剤の併用療法
JP2024516363A (ja) リボシクリブ及びアムセネストラントを含む組み合わせ
JP6860949B2 (ja) 癌の処置方法
JP2022514056A (ja) 癌の治療に使用するためのRaf阻害剤及びCDK4/6阻害剤による組み合わせ療法
JP7703124B1 (ja) Serd投薬レジメンの組み合わせを使用してがんを治療する方法
JP2012526772A (ja) ホスホイノシチド3−キナーゼ阻害剤および抗糖尿病性化合物の組合せ剤
AU2020381240C1 (en) Therapeutic combinations of acalabrutinib and capivasertib to treat B-cell malignancies
TW202434251A (zh) 治療癌症之療法
EA045670B1 (ru) Терапевтические комбинации акалабрутиниба и капивасертиба для лечения в-клеточных злокачественных образований
HK40069821B (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
HK40069821A (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
WO2026076264A1 (en) Treatment of lymphomas using an ezh2 inhibitor
HK40051622A (en) Combination therapy comprising a b-raf inhibitor and a second inhibitor
TW202508598A (zh) 癌症療法
EA040191B1 (ru) Комбинированная терапия

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240826

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240826

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241016

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250331

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250708

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250916

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250925

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250925

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251120

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251120

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251120

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260604

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260604